You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Ginkgo said that next-generation sequencing, coupled with its automation capabilities, has the potential to increase COVID-19 testing capacity.
Assays like SwabSeq, Dx-Seq, and LAMP-Seq promise to analyze tens to hundreds of thousands of samples in parallel but might be constrained by sample availability.
Although Illumina's failure to acquire Pacific Biosciences stood out in 2019, the upward trend in M&A activity in the omics space in 2018 continued last year.
Ginkgo plans to strategically partner with leading companies in mature markets to create synthetic biology-based spinouts, something it has already done in ag-bio.
Ginkgo will acquire Beacon optofluidic platforms from Berkeley Lights and incorporate them into its automated genetic engineering foundries.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.